ChemoMetec A/S (FRA:CHY)

ChemoMetec Statistics

Total Valuation

ChemoMetec has a market cap or net worth of EUR 1.78 billion. The enterprise value is 1.74 billion.

Market Cap	1.78B
Enterprise Value	1.74B

Important Dates

The next estimated earnings date is Wednesday, February 4, 2026.

Earnings Date	Feb 4, 2026
Ex-Dividend Date	Oct 10, 2025

Share Statistics

Current Share Class	17.40M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	3.75%
Owned by Institutions (%)	42.31%
Float	16.75M

Valuation Ratios

The trailing PE ratio is 71.23 and the forward PE ratio is 53.48.

PE Ratio	71.23
Forward PE	53.48
PS Ratio	26.79
PB Ratio	19.72
P/TBV Ratio	25.52
P/FCF Ratio	74.77
P/OCF Ratio	64.01
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 52.33, with an EV/FCF ratio of 72.89.

EV / Earnings	69.44
EV / Sales	26.15
EV / EBITDA	52.33
EV / EBIT	54.80
EV / FCF	72.89

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.01.

Current Ratio	3.70
Quick Ratio	2.91
Debt / Equity	0.01
Debt / EBITDA	0.03
Debt / FCF	0.04
Interest Coverage	378.43

Financial Efficiency

Return on equity (ROE) is 30.10% and return on invested capital (ROIC) is 23.67%.

Return on Equity (ROE)	30.10%
Return on Assets (ROA)	19.65%
Return on Invested Capital (ROIC)	23.67%
Return on Capital Employed (ROCE)	34.73%
Revenue Per Employee	390,782
Profits Per Employee	146,989
Employee Count	170
Asset Turnover	0.66
Inventory Turnover	0.26

Taxes

In the past 12 months, ChemoMetec has paid 7.19 million in taxes.

Income Tax	7.19M
Effective Tax Rate	22.34%

Stock Price Statistics

The stock price has increased by +63.42% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+63.42%
50-Day Moving Average	94.74
200-Day Moving Average	76.03
Relative Strength Index (RSI)	64.82
Average Volume (20 Days)	23

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ChemoMetec had revenue of EUR 66.43 million and earned 24.99 million in profits. Earnings per share was 1.44.

Revenue	66.43M
Gross Profit	62.40M
Operating Income	31.71M
Pretax Income	32.17M
Net Income	24.99M
EBITDA	33.20M
EBIT	31.71M
Earnings Per Share (EPS)	1.44

Balance Sheet

The company has 45.83 million in cash and 858,476 in debt, giving a net cash position of 44.97 million.

Cash & Cash Equivalents	45.83M
Total Debt	858,476
Net Cash	44.97M
Net Cash Per Share	n/a
Equity (Book Value)	90.27M
Book Value Per Share	5.19
Working Capital	53.11M

Cash Flow

In the last 12 months, operating cash flow was 27.81 million and capital expenditures -4.00 million, giving a free cash flow of 23.81 million.

Operating Cash Flow	27.81M
Capital Expenditures	-4.00M
Free Cash Flow	23.81M
FCF Per Share	n/a

Margins

Gross margin is 93.93%, with operating and profit margins of 47.73% and 37.61%.

Gross Margin	93.93%
Operating Margin	47.73%
Pretax Margin	48.43%
Profit Margin	37.61%
EBITDA Margin	49.98%
EBIT Margin	47.73%
FCF Margin	35.83%

Dividends & Yields

This stock pays an annual dividend of 0.94, which amounts to a dividend yield of 0.89%.

Dividend Per Share	0.94
Dividend Yield	0.89%
Dividend Growth (YoY)	74.73%
Years of Dividend Growth	n/a
Payout Ratio	37.34%
Buyback Yield	n/a
Shareholder Yield	0.89%
Earnings Yield	1.40%
FCF Yield	1.34%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ChemoMetec has an Altman Z-Score of 34.64 and a Piotroski F-Score of 5.

Altman Z-Score	34.64
Piotroski F-Score	5